News|Articles|October 19, 2021

COVID-19 Updates: Delta Variant, US Vaccinations, & Global Data as of October 19, 2021

Data from the CDC on the Delta variant and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

How widespread is the Delta variant (B.1.617.2) in the US?

According to early estimates from the Centers for Disease Control and Prevention (CDC), as of October 9, 2021, the SARS-CoV-2 Delta variant made up 99.9% of COVID-19 cases in the United States.

The CDC estimates for the week ending on October 9, 2021, the 5 states with the highest unweighted proportion of new cases attributed to the SARS-CoV-2 Delta variant are:

1. Vermont: 100%
2. Idaho: 99.7%
3. Maine: 99.7%
4. Massachusetts: 99.6%
5. Washington: 99.6%

How many people in the US have been vaccinated against COVID-19?

According to the CDC as of today, October 19, 2021, at 3:15 PM, EDT:

• 66% of total US population has received at least 1 dose
• 57.1% of total US population is fully vaccinated

The 5 states/territories with the highest percentage of population fully vaccinated are:

1. Puerto Rico: 72.2%
2. Vermont: 70.6%
3. Connecticut: 70%
4. Rhode Island: 70%
5. Maine: 69.8%

How many cases of COVID-19 have been confirmed in the US?

According to the Johns Hopkins COVID-19 interactive map, as of today, October 19, 2021 at 5:22 PM, EDT, there have been:

• 45 107 626 confirmed cases and
• 727 729 deaths

The 5 states with the highest total confirmed cases are:

1. California: 4 829 722
2. Texas: 4 190 014
3. Florida: 3 664 097
4. New York: 2 514 422
5. Illinois: 1 673 346

Deaths: California has the highest number of deaths due to COVID-19 with 70 870 reported fatalities, followed by Texas with 69 301 and Florida with 58 143.

How many cases of COVID-19 have been confirmed globally?

Globally, there have been 241 472 309 confirmed cases, 4 911 402 deaths, and 6 671 953 520 vaccine doses administered.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

November 21, 2025

Multimedia

Expert Illustrations and Commentaries™: The Role of the Paracellular Pathway in the Management of Hyperphosphatemia in CKD

Anil K. Agarwal, MD; Nissreen Elfadawy, MD, MSc, FASN

Multimedia

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Glenn M. Chertow, MD, MPH; Anjay Rastogi, MD, PhD

COVID-19 Updates: Delta Variant, US Vaccinations, & Global Data as of October 19, 2021

How widespread is the Delta variant (B.1.617.2) in the US?

How many people in the US have been vaccinated against COVID-19?

How many cases of COVID-19 have been confirmed in the US?

How many cases of COVID-19 have been confirmed globally?

Newsletter

Related Content

Inequities in Menopause Care: How Provider and Patient Factors Combine to Limit Treatment

Semaglutide CV Effects Appear Independent of Baseline Adiposity, Suggesting Disease-Modifying Potential

Donna Plecha, MD: Why You Should Start Breast Cancer Risk Assessment at Age 25

Topline Real-World Data Show Fezolinetant Improves VMS, Sleep, and Work Productivity in Women With Confirmed Menopausal VMS

Four Studies Build Evidence for Elinzanetant as a Safe, Effective Nonhormonal Option for Menopausal Vasomotor Symptoms

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Expert Illustrations and Commentaries™: The Role of the Paracellular Pathway in the Management of Hyperphosphatemia in CKD

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Identifying and Treating CIDP in the Modern Era

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Evolving Strategies and Emerging Agents in PTCL: Subtypes, Mutations, and Modern Therapies

Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment

Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Community Practice Connections™: 21st Annual Meeting of the International Society of Gastrointestinal Oncology

Medical Crossfire®: Optimal Approaches to Evaluating and Addressing Pain in the Patient With Sickle Cell Disease

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Addressing Health Care Inequities™: Taking a More Mindful Approach to the Care of Every Patient Presenting With ATTR-CM

Clinical Case Vignette Series™: 3rd Annual International Congress on Pediatric Oncology

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Medical Crossfire®: Improving Survival in HR-Positive HER2-Negative Metastatic Breast Cancer – Advances in Selective Estrogen Receptor Targeting Therapies

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

Real Psychiatry 2026

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

19th Annual New York GU Cancers Congress™

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting

43rd Annual Miami Breast Cancer Conference®

17th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision-Making and Future Therapies

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention

Homing in on the Role of PSMA in Prostate Cancer – Harnessing the Power of Precision Medicine Through Imaging and Therapy to Individualize Treatment Plans

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

2nd Annual Hawaii Cancer Conference

Interventional Glaucoma: The Convergence of Surgical Innovation and Therapeutic Hope

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Expert Perspectives on Technological Advances in Cataract Surgery

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis

Community Practice Connections™: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes

Raising Our Game in the Management of Hyperlipidemia: New Targets, New Tactics